# US 2021/0077512 A1 · Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0077512 A1
- Document ID: US20210077512A1
- Status: Published application
- Kind: A1
- Application number: 17/099,018
- Filed: 2020-11-16
- Published: 2021-03-18
- Earliest claimed: 2010-12-31
- Assignees: Abbott Laboratories
- Applicants: Abbott Laboratories
- Inventors: RACHAEL BUCK; GERALYN O. DUSKA-MCEWEN; JOSEPH P. SCHALLER
- Web page: https://patentgrep.com/patent/US20210077512A1

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 39/06: Free radical scavengers or antioxidants
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2200/3202: Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
- A23V 2200/324: having an effect on the immune system
- A23V 2250/1882: Polyunsaturated fatty acids
- A23V 2250/28: Oligosaccharides
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

## Claims

### Claim 1

A synthetic pediatric formula comprising:
hydrolyzed protein;
from about 0.01 mg/mL to about 10 mg/mL of at least one of 6′-sialyllactose, 3′-sialyllactose 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, and lacto-N-fucopentaose;
from about 0.080 mg/mL to about 0.250 mg/mL of arachidonic acid;
from about 0.001 μg/mL to about 5 μg/mL of at least one of lutein, lycopene, and beta-carotene;
from about 10 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;
wherein the synthetic pediatric formula is shelf stable for at least 3 months.

### Claim 2 (depends on 1)

The synthetic pediatric formula of claim 1 comprising 0.01 mg/mL to about 5 mg/mL of at least one of 2′-fucosyllactose, 3′-sialylactose, and 6′-sialyllactose.

### Claim 3 (depends on 1)

The synthetic pediatric formula of claim 1, wherein the human milk oligosaccharide component comprises 2′-fucosyllactose which is present in a concentration of from about 0.01 mg/mL to 5 mg/mL.

### Claim 4 (depends on 1)

The synthetic pediatric formula of claim 1, wherein the monomeric monophosphate nucleotide component is present in a concentration of from about 42 mg/L to about 102

### Claim 5 (depends on 1)

The synthetic pediatric formula of claim 1, wherein the monomeric monophosphate nucleotide component comprises cytidine 5′-monophosphate, adenosine 5′-monophosphate, guanosine 5′-monophosphate, and uridine 5′-monophosphate.

### Claim 6

The synthetic pediatric formula of claim I, wherein at least one monomeric monophosphate nucleotide is a free acid and at least one other monomeric monophosphate nucleotide is a salt.

### Claim 7 (depends on 1)

The synthetic pediatric formula of claim 1, comprising a combination of lutein, lycopene, and beta-carotene.

### Claim 8 (depends on 1)

The synthetic pediatric formula of claim 1, further comprising high oleic safflower oil, soybean oil, and coconut oil.

### Claim 9 (depends on 1)

The synthetic pediatric formula of claim 1, further comprising lactose, and fructooligosaccharide.

### Claim 10 (depends on 1)

The synthetic pediatric formula of claim 1, wherein the hydrolyzed protein is extensively hydrolyzed protein.

### Claim 11

A synthetic pediatric formula comprising:
hydrolyzed protein;
from about 0.01 mg/mL to about 10 mg/mL of at least one of 2′-fucosyllactose, 3-fucosyllactose, 6′-sialyllactose, 3′-sialylactose, and lacto-N-tetraose;
from about 0.080 mg/mL to about 0.250 mg/mL of arachidonic acid;
from about 0.001 μg/mL to about 5 μg/mL of at least one of lutein, lycopene, and beta-carotene;
from about 10 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component; and
wherein the synthetic pediatric formula is shelf stable from about 3 months to about 24 months.

### Claim 12 (depends on 11)

The synthetic pediatric formula of claim 11 comprising 3′-sialyllactose and 6′-sialyllactose in weight ratio of from about 1:2 to about 2:1.

### Claim 13 (depends on 11)

The synthetic pediatric formula of claim 11, wherein 2′-fucosyllactose is present in a concentration of from about 0.01 mg/mL to 5 mg/mL.

### Claim 14 (depends on 11)

The synthetic pediatric formula of claim 11, wherein the monomeric monophosphate nucleotide component is present in a concentration of from about 42 mg/L to about 102 mg/L.

### Claim 15 (depends on 11)

The synthetic pediatric formula of claim 11, wherein the monomeric monophosphate nucleotide component comprises cytidine 5′-monophosphate, adenosine 5′-monophosphate, guanosine 5′-monophosphate, and uridine 5′-monophosphate.

### Claim 16 (depends on 11)

The synthetic pediatric formula of claim 11, wherein the hydrolyzed protein is extensively hydrolyzed protein.

### Claim 17 (depends on 11)

The synthetic pediatric formula of claim 11, wherein at least one monomeric monophosphate nucleotide is a free acid and at least one other monomeric monophosphate nucleotide is a salt.

### Claim 18 (depends on 11)

The synthetic pediatric formula of claim 11, comprising a combination of lutein, lycopene, and beta-carotene

### Claim 19 (depends on 11)

The synthetic pediatric formula of claim 11, further comprising high oleic safflower oil, soybean oil, and coconut oil.

### Claim 20

A method of reducing inflammation in an infant, toddler, or child in need thereof, the method comprising administering to the infant, toddler, or child a synthetic pediatric formula comprising:
hydrolyzed protein;
from about 0.01 mg/mL to about 10 mg/mL of at least one of 6′-sialyllactose, 3′-sialyllactose 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, and lacto-N-neotetraose:
from about 0.080 mg/mL to about 0.250 mg/mL of arachidonic acid;
from about 0.001 μg/mL to about 5 μg/mL of at least one of lutein, lycopene, and beta-carotene;
from about 10 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;
wherein the synthetic pediatric formula is shelf stable for at least 3 months.
